Teva names acting CFO; FDA warns on Lovenox safety; Forest wraps more Bystolic suits;

@FiercePharma: Biggest new news online: Will Merck be next to join Big Pharma's asset sale parade? Story | Follow @FiercePharma

@CarlyHFierce: Does the Justice Department's off-label marketing enforcement actually deter bad behavior? With GSK, maybe. More | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) tapped Kobi Altman to serve as acting CFO after Eyal Desheh stepped up from that role to be interim CEO while the company searches for a replacement for Jeremy Levin. Report

> The FDA issued a new warning on Sanofi's ($SNY) blood thinner Lovenox and its generic copies, asking doctors to be careful inserting and removing spinal catheters in patients using it. Report

> Forest Laboratories ($FRX) wrapped up the last of its patent litigation over the blood pressure drug Bystolic, with a deal allowing Actavis ($ACT) and several other generics makers to sell their copies three months before a 2021 patent expires. Release

> Experts say broader criteria for diagnosing ADHD could lead to overtreatment in the U.S. to the tune of $500 million a year. Report

> The hedge fund Elliott International has built up a stake of almost 12% in the German drug distributor Celesio, which U.S.-based rival McKesson ($MCK) is seeking to buy for $8.3 billion. Report

Medical Device News

@FierceMedDev: ICYMI: Roche's Ventana to concoct companion Dx tests for Incyte's cancer drugs. More | Follow @FierceMedDev

@MarkHFierce: Biocept becomes the latest Dx company to outline its IPO terms - full speed ahead. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Gold nanoparticles first to deliver RNA to brain tumors. More from FierceDrugDelivery | Follow @MichaelGFierce

> Surefire bags $18.2M for cancer-treating catheters. More

> Bacterin turns to distributor for European expansion. Item

> Investors elated over HeartWare's stellar Q3 heart pump sales. Article

> Medtronic wins FDA nod to use software with competitors' tech. Story

Biotech News

@FierceBiotech: Novartis R&D will ax 500 staffers, boost Boston in global realignment. More | Follow @FierceBiotech

@JohnCFierce: Geron shares double on imetelstat data. Quite a reversal of fortune for Geron. Story | Follow @JohnCFierce

@DamianFierce: Medtronic wins FDA approval to use its software with competitors' tech. More | Follow @DamianFierce

@EmilyMFierce: Next Generation: Cancer Drug in Disguise. Article | Follow @EmilyMFierce

> Shire slashes R&D ops, refocuses pipeline as it restructures in Europe, U.S. News

> GlaxoSmithKline toes the line in Breo launch. Item

Pharma Manufacturing News

> Hospira CEO looks to better days as 'swamp draining' nears end. News

> Wholesaler McKesson settles another price-manipulation suit. Article

> FDA finally lifts warning letter on AMRI fill/finish facility. More

> Visa woes still stalling FDA plans for China inspections. Story

> Pfizer contractors testing new methods to clean up old production site. News

> Nosco hiring 51 staff for packaging and labeling plant. Item

Vaccines News

> Merck readies FDA submission for son of Gardasil. News

> Takeda, Boehringer invest to move CMV vaccine into clinic. Story

> European scientists join Sanofi, Pfizer in C. diff vaccine race. Article

> Study finds one HPV vaccine dose gives strong, durable immune response. News

> WHO massively scales up Middle East polio immunization plan. Story

> Shipping snafu prompts Navy review of vaccination procedures. Item

And Finally... The FDA proposes to all but eliminate artery-clogging trans fats in foods. Report (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.